Developer docs
API playgroundTry for free, no card

Search company profiles

iMediSync

Full company profile

uuid0002onu

Namestring
iMediSync
Legal namestring
주식회사 아이메디신 (iMediSync Co., Ltd.)
Websiteurl
imedisync.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

iMediSync (주식회사 아이메디신) is a Seoul, South Korea-based digital mental health company founded in 2012 by Seung Wan Kang (MD, PhD) that develops an integrated AI platform for brainwave-based screening and therapy. The system pairs dry-electrode wireless EEG headsets (iSyncWave, FDA 510(k) cleared; iSyncMe, 2023 entry-level variant) with a cloud-based AI analytics platform (iSyncBrain, FDA 510(k) Class II cleared) and an HRV-based cardiac analytics add-on (iSyncHeart). The proprietary stack rests on a sex- and age-differentiated EEG normative database built since 2013 in collaboration with Seoul National University, AI-automated denoising, sLORETA 3D source-level mapping, and clinically validated biomarkers for amnestic MCI (90.9% accuracy in a 442-dataset multi-site trial), Alzheimer's, Parkinson's, depression, stroke cognitive impairment, coma prognosis, Lewy body dementia, and pediatric ADHD. Devices integrate 850 nm near-infrared photobiomodulation therapy alongside 19-channel EEG plus PPG for HRV, enabling a sub-10-minute brain health scan.

The company generates revenue across four streams: hardware device sales (iSyncWave, iSyncMe) to hospitals and clinics, recurring SaaS subscriptions for iSyncBrain/iSyncHeart cloud analytics, software medical device licensing for FDA/KFDA-cleared products, and paid professional training (QEEG courses priced at KRW 100,000 per session, NeuroBridge 2025 Asia-Pacific workshop at USD 700). Pricing for hardware and SaaS is handled through direct sales quotation rather than public disclosure.

Customer base spans 60+ institutional users within six months of iSyncWave launch, 25+ Korean hospital partnerships (Seoul Asan, Seoul National University Bundang, Yonsei Severance, Boramae, Chung-Ang, etc.), government health programs (Gwangju AI ecosystem, Busan mobile medical checkup via Busan National University Hospital, Korea Public Procurement Service innovative prototype designation), pediatric education partnerships (KidsScholar), and research deployments (KAIST, Mila/Quebec AI Institute). International expansion is executed through authorized regional distributors in the US (Arcadia, CA subsidiary), Australia, Japan (jMediSync), Thailand, Taiwan, and Romania/Europe (Neuros Europe SRL), with Dubai/Middle East exploration via Myungra Co. The Lotte Healthcare/Cazzle partnership adds a consumer wellness distribution channel.

Short descriptiontext

iMediSync is a Seoul, South Korea-based digital mental health company that builds AI-powered dry-electrode EEG headsets (iSyncWave, iSyncMe) and cloud QEEG analytics (iSyncBrain, iSyncHeart) for hospitals, dementia centers, government health programs, and research institutions across 9+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital mental health, EEG brainwave analysis, photobiomodulation therapy, neurological biomarker detection, quantitative EEG platform
Industry5 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAD
Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAFAF
Wearables & Consumer IoT Integration Platforms (BYOD)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAFAO
Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services5182
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Digital Mental Health Diagnostics
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Hardware Device Sales (iSyncWave, iSyncMe)
TypeHardware Sales
Description

Sale of wireless dry EEG headset devices — iSyncWave (helmet form, weight 1600g) and iSyncMe (lighter entry model, 1200g). Both integrate EEG measurement with PBM LED therapy. Sold to hospitals, clinics, and government health programs directly and through distributors.

imedisync.com
2Cloud-Based AI Analytics Platform (iSyncBrain, iSyncHeart)
TypeSubscription Recurring
Description

SaaS subscription model for cloud-hosted QEEG and HRV analysis. iSyncBrain-C (clinical series), iSyncBrain-M (medical series for MCI), and iSyncBrain-R (research series) offered as software medical devices. Users access automated reports, brain mapping, and disease biomarkers via web/App.

imedisync.com
3Software Medical Device Licensing
TypeOne Time License
Description

Sales and distribution of FDA 510(k) and KFDA-cleared software medical devices — iSyncBrain-C (FDA K222838) and iSyncBrain-M1 (MCI Classifier). Licensed to medical institutions for clinical use in dementia early screening and brain health assessment.

imedisync.com
4Professional Services and Training
TypeProfessional Services
Description

Paid QEEG training programs for medical professionals — basic and advanced courses offered at 100,000 KRW per session. Educational workshops including NeuroBridge 2025 (Asia-Pacific, $700 USD registration fee).

imedisync.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details5 tiers
1QEEG Basic Training for Physicians
ModelOtherBilling cadenceOne-time
Notes

100,000 KRW per session (includes dinner). 4-hour offline practical session. Maximum 20 participants on first-come basis.

imedisync.com
2QEEG Advanced Training for Physicians
ModelOtherBilling cadenceOne-time
Notes

100,000 KRW per session (includes dinner). 4-hour offline practical session. Maximum 20 participants on first-come basis.

imedisync.com
3NeuroBridge 2025 Asia-Pacific Workshop
ModelOtherBilling cadenceOne-time
Notes

$700 USD registration fee (early bird 10% discount by July 25). Includes daily lunches, coffee breaks, and gala dinner on Day 2.

imedisync.com
4iSyncBrain Cloud Analytics SaaS
ModelSubscriptionBilling cadenceAnnual
Notes

Details not publicly disclosed. Contact sales for quotation.

imedisync.com
5iSyncWave and iSyncMe Hardware Devices
ModelUnit PricingBilling cadenceOne-time
Notes

Available via authorized distributors. Pricing not publicly disclosed on website.

imedisync.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1iSyncWave
Description

Wireless dry EEG measurement and therapy device with integrated EEG scanning and near-infrared photobiomodulation (PBM) capabilities. FDA 510K cleared Class 2 medical device.

imedisync.com
+3 more records
Core offering1 text field

iMediSync develops and sells wireless dry-electrode EEG headsets (iSyncWave and iSyncMe) integrated with near-infrared photobiomodulation (PBM) therapy, connected to a cloud-based AI analytics platform (iSyncBrain for QEEG analysis, iSyncHeart for HRV analysis). The platform performs automated brain health screening, age- and sex-normed comparison, and AI-based disease biomarker detection for conditions such as Alzheimer's, amnestic mild cognitive impairment, Parkinson's, depression, and stroke cognitive impairment. The offering is sold as regulated medical device hardware plus SaaS analytics subscriptions to hospitals, clinics, government health programs, and wellness/senior care operators.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Amnestic MCI detection accuracy of 90.9% (sensitivity 93.2%, specificity 90.2%) in multi-site clinical trial with 442 EEG datasets
+3 more records
Product overview1 text field

iMediSync offers an integrated AI digital mental healthcare platform consisting of hardware devices and cloud-based software. The portfolio centers on iSyncWave and iSyncMe wearable EEG headsets with integrated photobiomodulation (PBM) therapy, which connect to the iSyncBrain cloud analytics platform for AI-powered brain health assessment. iSyncBrain provides multiple product lines (M for medical/dementia screening, C for clinical norm comparison, R for research) while iSyncHeart extends the platform to cardiac autonomic analysis via HRV. Together, the platform enables 10-minute brain health screening with automated QEEG analysis, disease biomarker detection (aMCI, Alzheimer's, depression), and guided digital therapeutics.

Product and service4 records
1iSyncWave
CategoryMedical Device Hardware
Description

Wireless dry-type EEG measurement headset with integrated near-infrared photobiomodulation (PBM) therapy. Features 19-channel dry EEG with automatic International 10/20 positioning, PPG sensor for HRV measurement, and 850nm NIR-LED therapy. Enables 10-minute brain health measurement and analysis cycle without gel electrodes. FDA 510(k) cleared (K220056) and KFDA Class 2 medical device. Sold to hospitals, clinics, dementia centers, and government health programs for neurological screening and digital therapeutics.

2iSyncMe
CategoryMedical Device Hardware
Description

Lightweight wireless dry-electrode EEG headset with integrated photobiomodulation (PBM) therapy, positioned as a next-generation entry-level device. Features improved signal quality accuracy, lighter weight (1200g), enhanced PBM performance, flexible auto-fit banding for all head sizes (41.5cm to 64.2cm), and remote mental care capability. Combines 19-channel dry EEG with 850nm NIR-LED photobiomodulation.

3iSyncBrain
CategoryCloud AI Analytics Software
Description

Cloud-based AI EEG analytics platform offered in three series: iSyncBrain-M (Medical) for dementia early detection and amnestic MCI screening with disease biomarkers; iSyncBrain-C (Clinical) for healthy norm comparisons at sensor and source levels; iSyncBrain-R (Research) for group statistics and placebo-controlled studies. Features AI-automated denoising, 3D brain mapping (sLORETA), and AI-based biomarker reports compared against the world's first sex- and age-differentiated EEG normative database. FDA 510(k) cleared (K222838) and KFDA software medical device. Delivered via SaaS subscription on web and Android app.

4iSyncHeart
CategoryCloud AI Analytics Software
Description

HRV-based machine learning biomarker solution for depression/anxiety detection and stress profiling. Provides automated HRV extraction and standardization, emotion analysis, sympathovagal balance assessment, and GAS (General Adaptation Syndrome) phase stress analysis based on heart rate variability norms. KFDA-registered medical device. Used across clinical fields including psychiatry, cardiology, and wellness programs.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership35 partners
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2024-03-25
Description

MOU as part of Gwangju's AI industry ecosystem initiative (175th–182nd partnership). iMediSync to establish a regional office in Gwangju for AI mental healthcare technology development. Collaboration on talent cultivation, job creation, and AI industry ecosystem support leveraging Gwangju's National AI Data Center infrastructure.

2Lotte Healthcare
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-16
Description

MOU for joint development of AI-based healthcare business models in wellness and senior care. Lotte Healthcare's personalized health management platform 'Cazzle' will integrate iMediSync's brainwave measurement services. Long-term branding and marketing cooperation planned alongside technology development.

imedisync.com
3KidsScholar
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2023-08-03
Description

MOU for mutual collaboration in early childhood education and brain health. Planned services include brainwave measurement for KidsScholar VIP customers, integration of brain analysis with reading effectiveness evaluation, joint marketing, and service pilot programs for child development applications.

imedisync.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-05-30
Description

Partnership with Mila, the world's largest academic deep learning research institute founded by Professor Yoshua Bengio, to advance AI-driven mental healthcare. The collaboration aims to develop cutting-edge solutions for detecting and addressing brain dysfunctions, combining Mila's AI research prowess with iMediSync's EEG-based digital mental health platform.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2022-09-08
Description

iSyncWave introduced to Busan City's visiting mobile medical checkup system ('door-to-door health service'). Implemented at Busan National University Hospital's medical bus equipped with portable ultrasound, X-ray, and EEG. First nationwide implementation of EEG in mobile health screening.

6Seoul Asan Hospital (서울아산병원)
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2022-09-06
Description

Joint research MOU for developing digital diagnosis and treatment methods for Parkinson's disease. Research collaboration using QEEG biomarkers for Parkinson's pathology detection and digital therapeutic monitoring.

imedisync.com
7Seoul National University Hospital (서울대병원)
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2022-06-07
Description

Research collaboration for brain stroke treatment studies using iSyncBrain EEG analysis technology. Joint development of digital biomarkers for stroke rehabilitation prognosis and cognitive impairment prediction.

imedisync.com
8iMediSync North America Inc.
Strategic tierKeyTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-07-01
Description

US subsidiary and authorized distributor for North America. Contact: kody@imedisync.com, +1-480-229-0054. Office located in Arcadia, California. Handles US sales, distribution, and customer support for the North American market.

imedisync.com
9iMediSync Australia Inc.
Strategic tierKeyTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-07-01
Description

Authorized distributor for Australia and potentially broader Oceania. Located in Tweed Heads, NSW. Contact: admin@imedisyncaustralasia.com.au. Website: imedisyncaustralasia.com.au.

imedisync.com
10jMediSync Inc.
Strategic tierKeyTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-07-01
Description

Authorized distributor for Japan. Located in Minato-ku, Tokyo. Contact: h.yoshida@jmedisync.com, +81-3-3593-5270. Serving the Japanese healthcare market with iMediSync products.

imedisync.com
11IMEDISYNC(THAILAND) Co., Ltd.
Strategic tierKeyTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-07-01
Description

Authorized distributor for Thailand. Located in Bangkok. Contact: suan@mastermakerth.com, +66-2-276-4388. Distributing iMediSync EEG and mental health solutions in the Thai market.

imedisync.com
12Chun International Co. LTD.
Strategic tierKeyTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-07-01
Description

Authorized distributor for Taiwan. Located in New Taipei City. Contact: GreatLin@ci-med.com. Distributing iMediSync products in the Taiwan market.

imedisync.com
13Neuros Europe SRL
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-07-01
Description

Exclusive distributor for Romania and broader Europe, led by CEO Diana Palotos who surpassed annual sales targets in the first 12 months of partnership (2025). Contact: contact@neuros.ro, +40 744 134510. Websites: neuros.ro and imedisync-neuros.com/en. Successfully driving European market expansion.

imedisync.com
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2021-06-23
Description

MOU signed with KAIST President Lee Guang-hee for brain disease prevention research collaboration. Academic partnership leveraging KAIST's neuroscience and AI research capabilities for digital mental healthcare development.

15Seoul St. Mary's Hospital, The Catholic University of Korea
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

MOU for academic exchange and joint research in brain neural network studies. Collaboration on developing biomarkers and clinical applications using iSyncBrain's standardized QEEG analysis platform.

imedisync.com
16Seoul National University Boramae Medical Center
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Research collaboration MOU for developing EEG-based biomarkers and clinical applications. Partnership for early detection of dementia and neurodegenerative diseases using iSyncBrain QEEG analysis platform.

imedisync.com
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Clinical trial site for amnestic MCI EEG biomarker validation. 103 aMCI and 339 normal control EEG datasets collected and analyzed using iSyncBrain. Key clinical validation partner for regulatory submissions to KFDA.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Clinical trial site for aMCI EEG biomarker development. Partnership for validation of QEEG-based mild cognitive impairment screening technology.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Clinical trial site for aMCI EEG biomarker validation as part of the confirmatory clinical study for iSyncBrain-M1 KFDA registration.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Academic collaboration for brain health research and clinical applications using QEEG analysis technology.

21Hanyang University Seoul Hospital
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Research partnership for developing QEEG-based biomarkers and digital therapeutics for neurological disorders.

imedisync.com
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Collaboration on dementia research and brain health analysis. Partnership combining Dong-A University's academic resources with Busan's metropolitan dementia care infrastructure.

23Ewha Womans University Seoul Hospital
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Academic collaboration for QEEG research in neurological and psychiatric conditions.

imedisync.com
24Seoul University of Buddhism Neuroscience Research Institute
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Academic partnership for neuroscience research combining Buddhist medicine perspectives with QEEG-based brain analysis technology.

imedisync.com
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Research collaboration for developing QEEG biomarkers for Lewy body dementia, depression, and other psychiatric conditions. Wide-ranging clinical research partnership.

26University of Ulsan Asan Medical Center
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Clinical research collaboration for developing and validating digital biomarkers for various brain diseases using iSyncBrain QEEG analysis platform.

imedisync.com
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Rehabilitation medicine research collaboration for developing QEEG-guided digital therapeutics, particularly for cerebral palsy and rehabilitation applications.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Research collaboration for Parkinson's disease studies and QEEG biomarker development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Academic collaboration for QEEG research in neurological conditions and digital biomarker development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Pediatric research collaboration for developing EEG-based biomarkers for attention and developmental disorders in children.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Academic collaboration for QEEG research targeting PTSD, addiction, and related psychiatric conditions.

32Ajou University Hospital
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Research collaboration for developing QEEG biomarkers for cognitive impairment and MCI.

imedisync.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-09
Description

Collaboration for neurorehabilitation research and QEEG applications in brain injury rehabilitation.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2020-01-08
Description

MOU for 'smart healthcare service topic discovery based on consumer data'. Collaboration between Dong-A University's LINC+ program, Busan Metropolitan Dementia Center, and iMediSync for data-driven dementia care services.

35Myungra Co., Ltd (명라)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-12-03
Description

Discussion meeting for activating remote healthcare services with Dubai local medical institutions. Myungra Co. and iMediSync met with Dubai medical institution representatives including Dr. Kyungsang Oh to explore telemedicine and brainwave diagnostic technology deployment in the Middle East market.

imedisync.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based company developing FDA-cleared EEG-based AI assessments for concussion and brain injury. Comparable to iMediSync as an EEG hardware + cloud-AI biomarker company pursuing FDA clearances for clinical brain injury and neurological condition triage in hospital and potentially consumer settings.

TypeDirect peer
Description

US/Australia-based EEG hardware and software company offering consumer and research-grade dry-electrode headsets with cloud-based brain data analytics. Comparable to iMediSync on the dry-electrode EEG hardware + cloud analytics product architecture, though focused more on consumer/research than clinical.

TypeEmerging player
Description

US-based neurotechnology company building EEG-enabled wearable devices and brain-computer interface software for productivity, wellness, and clinical applications. Comparable as an emerging EEG wearable and analytics peer, with overlap in consumer/wellness brain health use cases adjacent to iMediSync's iSyncMe.

TypeDirect peer
Description

US-based point-of-care EEG company with FDA-cleared rapid brain monitoring and AI-assisted seizure detection. Comparable to iMediSync as a clinical AI-EEG platform with FDA-cleared hardware and software targeting hospital neurology decision-making, though focused on acute care rather than dementia screening.

TypeEmerging player
Description

France-based neurotechnology company with a consumer EEG headband for sleep and cognitive monitoring, plus a clinical research arm developing EEG biomarkers. Comparable to iMediSync on dry EEG + cloud biomarker platform strategy, though primarily consumer/sleep-oriented rather than dementia.

TypeDirect peer
Description

Ireland/UK-based company building a multi-domain EEG and digital biomarker platform for CNS clinical trials and patient monitoring. Comparable to iMediSync's iSyncBrain-R research series and biomarker development for depression, MCI, and related neurological indications.

TypeDirect peer
Description

US-based company offering EEG-guided neuromodulation therapies for brain health conditions including TBI and cognitive decline. Direct peer because of the QEEG-guided treatment paradigm, including use of photobiomodulation-style stimulation, mirroring iMediSync's iSyncWave diagnostic-plus-therapy model.

TypeDirect peer
Description

Australia-based manufacturer of clinical EEG, sleep diagnostics, and neurology devices. Directly comparable to iMediSync as a hardware + software neurodiagnostic platform selling to hospitals and sleep/neurology clinics globally, with overlapping customer segments in neurology and brain health assessment.

TypeDirect peer
Description

Spain-based company combining dry/multichannel EEG with transcranial current stimulation (tDCS/tACS) for clinical and research neuromodulation. Directly comparable to iMediSync in integrating EEG measurement with non-invasive brain stimulation therapies and offering cloud-based analysis.

TypeBroad incumbent
Description

US-listed incumbent in neurodiagnostic, EEG, and newborn screening equipment. Comparable as a broad EEG/neurology hardware incumbent selling to hospitals worldwide, though its portfolio spans many adjacent device categories beyond iMediSync's brain health focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iMediSync

Digital Mental Health Diagnosticsimedisync.com

iMediSync is a Seoul, South Korea-based digital mental health company that builds AI-powered dry-electrode EEG headsets (iSyncWave, iSyncMe) and cloud QEEG analytics (iSyncBrain, iSyncHeart) for hospitals, dementia centers, government health programs, and research institutions across 9+ countries.

What iMediSync does

iMediSync (주식회사 아이메디신) is a Seoul, South Korea-based digital mental health company founded in 2012 by Seung Wan Kang (MD, PhD) that develops an integrated AI platform for brainwave-based screening and therapy. The system pairs dry-electrode wireless EEG headsets (iSyncWave, FDA 510(k) cleared; iSyncMe, 2023 entry-level variant) with a cloud-based AI analytics platform (iSyncBrain, FDA 510(k) Class II cleared) and an HRV-based cardiac analytics add-on (iSyncHeart). The proprietary stack rests on a sex- and age-differentiated EEG normative database built since 2013 in collaboration with Seoul National University, AI-automated denoising, sLORETA 3D source-level mapping, and clinically validated biomarkers for amnestic MCI (90.9% accuracy in a 442-dataset multi-site trial), Alzheimer's, Parkinson's, depression, stroke cognitive impairment, coma prognosis, Lewy body dementia, and pediatric ADHD. Devices integrate 850 nm near-infrared photobiomodulation therapy alongside 19-channel EEG plus PPG for HRV, enabling a sub-10-minute brain health scan.

The company generates revenue across four streams: hardware device sales (iSyncWave, iSyncMe) to hospitals and clinics, recurring SaaS subscriptions for iSyncBrain/iSyncHeart cloud analytics, software medical device licensing for FDA/KFDA-cleared products, and paid professional training (QEEG courses priced at KRW 100,000 per session, NeuroBridge 2025 Asia-Pacific workshop at USD 700). Pricing for hardware and SaaS is handled through direct sales quotation rather than public disclosure.

Customer base spans 60+ institutional users within six months of iSyncWave launch, 25+ Korean hospital partnerships (Seoul Asan, Seoul National University Bundang, Yonsei Severance, Boramae, Chung-Ang, etc.), government health programs (Gwangju AI ecosystem, Busan mobile medical checkup via Busan National University Hospital, Korea Public Procurement Service innovative prototype designation), pediatric education partnerships (KidsScholar), and research deployments (KAIST, Mila/Quebec AI Institute). International expansion is executed through authorized regional distributors in the US (Arcadia, CA subsidiary), Australia, Japan (jMediSync), Thailand, Taiwan, and Romania/Europe (Neuros Europe SRL), with Dubai/Middle East exploration via Myungra Co. The Lotte Healthcare/Cazzle partnership adds a consumer wellness distribution channel.

iMediSync firmographics

Firmographics
Name
iMediSync
Legal name
주식회사 아이메디신 (iMediSync Co., Ltd.)
Website
https://imedisync.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
iMediSync is a Seoul, South Korea-based digital mental health company that builds AI-powered dry-electrode EEG headsets (iSyncWave, iSyncMe) and cloud QEEG analytics (iSyncBrain, iSyncHeart) for hospitals, dementia centers, government health programs, and research institutions across 9+ countries.
Ownership category
akta.pro rank

iMediSync industry classification

Industry
Product category
Digital Mental Health Diagnostics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182), Medical and Diagnostic Laboratories (62151)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAD
Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAFAF
Wearables & Consumer IoT Integration Platforms (BYOD)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAFAO
Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Digital mental health
  • EEG brainwave analysis
  • Photobiomodulation therapy
  • Neurological biomarker detection
  • Quantitative EEG platform

Where iMediSync is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices7 records

Markets served

iMediSync business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Hardware Device Sales (iSyncWave, iSyncMe): Sale of wireless dry EEG headset devices — iSyncWave (helmet form, weight 1600g) and iSyncMe (lighter entry model, 1200g). Both integrate EEG measurement with PBM LED therapy. Sold to hospitals, clinics, and government health programs directly and through distributors.
  2. Cloud-Based AI Analytics Platform (iSyncBrain, iSyncHeart): SaaS subscription model for cloud-hosted QEEG and HRV analysis. iSyncBrain-C (clinical series), iSyncBrain-M (medical series for MCI), and iSyncBrain-R (research series) offered as software medical devices. Users access automated reports, brain mapping, and disease biomarkers via web/App.
  3. Software Medical Device Licensing: Sales and distribution of FDA 510(k) and KFDA-cleared software medical devices — iSyncBrain-C (FDA K222838) and iSyncBrain-M1 (MCI Classifier). Licensed to medical institutions for clinical use in dementia early screening and brain health assessment.
  4. Professional Services and Training: Paid QEEG training programs for medical professionals — basic and advanced courses offered at 100,000 KRW per session. Educational workshops including NeuroBridge 2025 (Asia-Pacific, $700 USD registration fee).

Pricing tiers

ModelBillingPrice
OtherOne-timeQEEG Basic Training for Physicians
OtherOne-timeQEEG Advanced Training for Physicians
OtherOne-timeNeuroBridge 2025 Asia-Pacific Workshop
SubscriptionAnnualiSyncBrain Cloud Analytics SaaS
Unit PricingOne-timeiSyncWave and iSyncMe Hardware Devices

Go-to-market motion4 records

Distribution channels5 records

Marketing channels6 records

iMediSync product offering

Product offering

Core offering

iMediSync develops and sells wireless dry-electrode EEG headsets (iSyncWave and iSyncMe) integrated with near-infrared photobiomodulation (PBM) therapy, connected to a cloud-based AI analytics platform (iSyncBrain for QEEG analysis, iSyncHeart for HRV analysis). The platform performs automated brain health screening, age- and sex-normed comparison, and AI-based disease biomarker detection for conditions such as Alzheimer's, amnestic mild cognitive impairment, Parkinson's, depression, and stroke cognitive impairment. The offering is sold as regulated medical device hardware plus SaaS analytics subscriptions to hospitals, clinics, government health programs, and wellness/senior care operators.

Product overview

iMediSync offers an integrated AI digital mental healthcare platform consisting of hardware devices and cloud-based software. The portfolio centers on iSyncWave and iSyncMe wearable EEG headsets with integrated photobiomodulation (PBM) therapy, which connect to the iSyncBrain cloud analytics platform for AI-powered brain health assessment. iSyncBrain provides multiple product lines (M for medical/dementia screening, C for clinical norm comparison, R for research) while iSyncHeart extends the platform to cardiac autonomic analysis via HRV. Together, the platform enables 10-minute brain health screening with automated QEEG analysis, disease biomarker detection (aMCI, Alzheimer's, depression), and guided digital therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

  • iSyncWave: Wireless dry EEG measurement and therapy device with integrated EEG scanning and near-infrared photobiomodulation (PBM) capabilities. FDA 510K cleared Class 2 medical device.
  • iSyncBrain
  • iSyncHeart
  • iSyncMe

Products and services

  • iSyncWave Wireless dry-type EEG measurement headset with integrated near-infrared photobiomodulation (PBM) therapy. Features 19-channel dry EEG with automatic International 10/20 positioning, PPG sensor for HRV measurement, and 850nm NIR-LED therapy. Enables 10-minute brain health measurement and analysis cycle without gel electrodes. FDA 510(k) cleared (K220056) and KFDA Class 2 medical device. Sold to hospitals, clinics, dementia centers, and government health programs for neurological screening and digital therapeutics.
  • iSyncMe Lightweight wireless dry-electrode EEG headset with integrated photobiomodulation (PBM) therapy, positioned as a next-generation entry-level device. Features improved signal quality accuracy, lighter weight (1200g), enhanced PBM performance, flexible auto-fit banding for all head sizes (41.5cm to 64.2cm), and remote mental care capability. Combines 19-channel dry EEG with 850nm NIR-LED photobiomodulation.
  • iSyncBrain Cloud-based AI EEG analytics platform offered in three series: iSyncBrain-M (Medical) for dementia early detection and amnestic MCI screening with disease biomarkers; iSyncBrain-C (Clinical) for healthy norm comparisons at sensor and source levels; iSyncBrain-R (Research) for group statistics and placebo-controlled studies. Features AI-automated denoising, 3D brain mapping (sLORETA), and AI-based biomarker reports compared against the world's first sex- and age-differentiated EEG normative database. FDA 510(k) cleared (K222838) and KFDA software medical device. Delivered via SaaS subscription on web and Android app.
  • iSyncHeart HRV-based machine learning biomarker solution for depression/anxiety detection and stress profiling. Provides automated HRV extraction and standardization, emotion analysis, sympathovagal balance assessment, and GAS (General Adaptation Syndrome) phase stress analysis based on heart rate variability norms. KFDA-registered medical device. Used across clinical fields including psychiatry, cardiology, and wellness programs.

Quantifiable outcome

  • Amnestic MCI detection accuracy of 90.9% (sensitivity 93.2%, specificity 90.2%) in multi-site clinical trial with 442 EEG datasets
  • +3 more outcomes

Companies that use iMediSync

Customer profile

Segments5 records

Ideal customer profiles4 records

iMediSync technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

iMediSync partnerships and signals

Strategic signal

Partnerships

35 partnerships are on record, tiered key, core and minor.

  • Gwangju Metropolitan CitykeyStrategic or Co-development Partner · 25 March 2024MOU as part of Gwangju's AI industry ecosystem initiative (175th–182nd partnership). iMediSync to establish a regional office in Gwangju for AI mental healthcare technology development. Collaboration on talent cultivation, job creation, and AI industry ecosystem support leveraging Gwangju's National AI Data Center infrastructure.
  • Lotte HealthcarecoreStrategic or Co-development Partner · 16 August 2023MOU for joint development of AI-based healthcare business models in wellness and senior care. Lotte Healthcare's personalized health management platform 'Cazzle' will integrate iMediSync's brainwave measurement services. Long-term branding and marketing cooperation planned alongside technology development.
  • KidsScholarkeyStrategic or Co-development Partner · 3 August 2023MOU for mutual collaboration in early childhood education and brain health. Planned services include brainwave measurement for KidsScholar VIP customers, integration of brain analysis with reading effectiveness evaluation, joint marketing, and service pilot programs for child development applications.
  • Mila (Quebec AI Institute)coreTechnology or Integration · 30 May 2023Partnership with Mila, the world's largest academic deep learning research institute founded by Professor Yoshua Bengio, to advance AI-driven mental healthcare. The collaboration aims to develop cutting-edge solutions for detecting and addressing brain dysfunctions, combining Mila's AI research prowess with iMediSync's EEG-based digital mental health platform.
  • Busan Metropolitan City / Busan National University HospitalkeyStrategic or Co-development Partner · 8 September 2022iSyncWave introduced to Busan City's visiting mobile medical checkup system ('door-to-door health service'). Implemented at Busan National University Hospital's medical bus equipped with portable ultrasound, X-ray, and EEG. First nationwide implementation of EEG in mobile health screening.
  • Seoul Asan Hospital (서울아산병원)keyStrategic or Co-development Partner · 6 September 2022Joint research MOU for developing digital diagnosis and treatment methods for Parkinson's disease. Research collaboration using QEEG biomarkers for Parkinson's pathology detection and digital therapeutic monitoring.
  • Seoul National University Hospital (서울대병원)keyStrategic or Co-development Partner · 7 June 2022Research collaboration for brain stroke treatment studies using iSyncBrain EEG analysis technology. Joint development of digital biomarkers for stroke rehabilitation prognosis and cognitive impairment prediction.
  • iMediSync North America Inc.keyChannel Partner/ Reseller/ Distributor · 1 July 2021US subsidiary and authorized distributor for North America. Contact: kody@imedisync.com, +1-480-229-0054. Office located in Arcadia, California. Handles US sales, distribution, and customer support for the North American market.
  • iMediSync Australia Inc.keyChannel Partner/ Reseller/ Distributor · 1 July 2021Authorized distributor for Australia and potentially broader Oceania. Located in Tweed Heads, NSW. Contact: admin@imedisyncaustralasia.com.au. Website: imedisyncaustralasia.com.au.
  • jMediSync Inc.keyChannel Partner/ Reseller/ Distributor · 1 July 2021Authorized distributor for Japan. Located in Minato-ku, Tokyo. Contact: h.yoshida@jmedisync.com, +81-3-3593-5270. Serving the Japanese healthcare market with iMediSync products.
  • IMEDISYNC(THAILAND) Co., Ltd.keyChannel Partner/ Reseller/ Distributor · 1 July 2021Authorized distributor for Thailand. Located in Bangkok. Contact: suan@mastermakerth.com, +66-2-276-4388. Distributing iMediSync EEG and mental health solutions in the Thai market.
  • Chun International Co. LTD.keyChannel Partner/ Reseller/ Distributor · 1 July 2021Authorized distributor for Taiwan. Located in New Taipei City. Contact: GreatLin@ci-med.com. Distributing iMediSync products in the Taiwan market.
  • Neuros Europe SRLcoreChannel Partner/ Reseller/ Distributor · 1 July 2021Exclusive distributor for Romania and broader Europe, led by CEO Diana Palotos who surpassed annual sales targets in the first 12 months of partnership (2025). Contact: contact@neuros.ro, +40 744 134510. Websites: neuros.ro and imedisync-neuros.com/en. Successfully driving European market expansion.
  • KAIST (Korea Advanced Institute of Science and Technology)keyStrategic or Co-development Partner · 23 June 2021MOU signed with KAIST President Lee Guang-hee for brain disease prevention research collaboration. Academic partnership leveraging KAIST's neuroscience and AI research capabilities for digital mental healthcare development.
  • Seoul St. Mary's Hospital, The Catholic University of KoreakeyStrategic or Co-development Partner · 9 January 2020MOU for academic exchange and joint research in brain neural network studies. Collaboration on developing biomarkers and clinical applications using iSyncBrain's standardized QEEG analysis platform.
  • Seoul National University Boramae Medical CenterkeyStrategic or Co-development Partner · 9 January 2020Research collaboration MOU for developing EEG-based biomarkers and clinical applications. Partnership for early detection of dementia and neurodegenerative diseases using iSyncBrain QEEG analysis platform.
  • Chung-Ang University HospitalkeyStrategic or Co-development Partner · 9 January 2020Clinical trial site for amnestic MCI EEG biomarker validation. 103 aMCI and 339 normal control EEG datasets collected and analyzed using iSyncBrain. Key clinical validation partner for regulatory submissions to KFDA.
  • Seoul National University Bundang HospitalkeyStrategic or Co-development Partner · 9 January 2020Clinical trial site for aMCI EEG biomarker development. Partnership for validation of QEEG-based mild cognitive impairment screening technology.
  • Kangwon National University HospitalkeyStrategic or Co-development Partner · 9 January 2020Clinical trial site for aMCI EEG biomarker validation as part of the confirmatory clinical study for iSyncBrain-M1 KFDA registration.
  • Hallym University Chuncheon Sacred Heart HospitalminorStrategic or Co-development Partner · 9 January 2020Academic collaboration for brain health research and clinical applications using QEEG analysis technology.
  • Hanyang University Seoul HospitalminorStrategic or Co-development Partner · 9 January 2020Research partnership for developing QEEG-based biomarkers and digital therapeutics for neurological disorders.
  • Dong-A University LINC+ & Busan Metropolitan Dementia CenterkeyStrategic or Co-development Partner · 9 January 2020Collaboration on dementia research and brain health analysis. Partnership combining Dong-A University's academic resources with Busan's metropolitan dementia care infrastructure.
  • Ewha Womans University Seoul HospitalminorStrategic or Co-development Partner · 9 January 2020Academic collaboration for QEEG research in neurological and psychiatric conditions.
  • Seoul University of Buddhism Neuroscience Research InstituteminorStrategic or Co-development Partner · 9 January 2020Academic partnership for neuroscience research combining Buddhist medicine perspectives with QEEG-based brain analysis technology.
  • Yonsei University Health System (Severance Hospital)keyStrategic or Co-development Partner · 9 January 2020Research collaboration for developing QEEG biomarkers for Lewy body dementia, depression, and other psychiatric conditions. Wide-ranging clinical research partnership.
  • University of Ulsan Asan Medical CenterkeyStrategic or Co-development Partner · 9 January 2020Clinical research collaboration for developing and validating digital biomarkers for various brain diseases using iSyncBrain QEEG analysis platform.
  • CHA University Bundang Medical CenterkeyStrategic or Co-development Partner · 9 January 2020Rehabilitation medicine research collaboration for developing QEEG-guided digital therapeutics, particularly for cerebral palsy and rehabilitation applications.
  • Korea University Ansan HospitalminorStrategic or Co-development Partner · 9 January 2020Research collaboration for Parkinson's disease studies and QEEG biomarker development.
  • Inha University HospitalminorStrategic or Co-development Partner · 9 January 2020Academic collaboration for QEEG research in neurological conditions and digital biomarker development.
  • Soon Chun Hyang University Hospital BucheonminorStrategic or Co-development Partner · 9 January 2020Pediatric research collaboration for developing EEG-based biomarkers for attention and developmental disorders in children.
  • Dongguk University Ilsan HospitalminorStrategic or Co-development Partner · 9 January 2020Academic collaboration for QEEG research targeting PTSD, addiction, and related psychiatric conditions.
  • Ajou University HospitalminorStrategic or Co-development Partner · 9 January 2020Research collaboration for developing QEEG biomarkers for cognitive impairment and MCI.
  • Bobath Memorial HospitalminorStrategic or Co-development Partner · 9 January 2020Collaboration for neurorehabilitation research and QEEG applications in brain injury rehabilitation.
  • Dong-A University / Busan Metropolitan Dementia Center MOU GroupkeyStrategic or Co-development Partner · 8 January 2020MOU for 'smart healthcare service topic discovery based on consumer data'. Collaboration between Dong-A University's LINC+ program, Busan Metropolitan Dementia Center, and iMediSync for data-driven dementia care services.
  • Myungra Co., Ltd (명라)minorStrategic or Co-development Partner · 3 December 2019Discussion meeting for activating remote healthcare services with Dubai local medical institutions. Myungra Co. and iMediSync met with Dubai medical institution representatives including Dr. Kyungsang Oh to explore telemedicine and brainwave diagnostic technology deployment in the Middle East market.

Scale indicators6 records

Recent moves8 records

Expansion highlights8 records

iMediSync competitors and assessment

Company assessment

Direct peers

  • BrainScope: US-based company developing FDA-cleared EEG-based AI assessments for concussion and brain injury. Comparable to iMediSync as an EEG hardware + cloud-AI biomarker company pursuing FDA clearances for clinical brain injury and neurological condition triage in hospital and potentially consumer settings.
  • Emotiv: US/Australia-based EEG hardware and software company offering consumer and research-grade dry-electrode headsets with cloud-based brain data analytics. Comparable to iMediSync on the dry-electrode EEG hardware + cloud analytics product architecture, though focused more on consumer/research than clinical.
  • Ceribell: US-based point-of-care EEG company with FDA-cleared rapid brain monitoring and AI-assisted seizure detection. Comparable to iMediSync as a clinical AI-EEG platform with FDA-cleared hardware and software targeting hospital neurology decision-making, though focused on acute care rather than dementia screening.
  • Cumulus Neuroscience: Ireland/UK-based company building a multi-domain EEG and digital biomarker platform for CNS clinical trials and patient monitoring. Comparable to iMediSync's iSyncBrain-R research series and biomarker development for depression, MCI, and related neurological indications.
  • Wave Neuroscience: US-based company offering EEG-guided neuromodulation therapies for brain health conditions including TBI and cognitive decline. Direct peer because of the QEEG-guided treatment paradigm, including use of photobiomodulation-style stimulation, mirroring iMediSync's iSyncWave diagnostic-plus-therapy model.
  • Compumedics: Australia-based manufacturer of clinical EEG, sleep diagnostics, and neurology devices. Directly comparable to iMediSync as a hardware + software neurodiagnostic platform selling to hospitals and sleep/neurology clinics globally, with overlapping customer segments in neurology and brain health assessment.
  • Neuroelectrics: Spain-based company combining dry/multichannel EEG with transcranial current stimulation (tDCS/tACS) for clinical and research neuromodulation. Directly comparable to iMediSync in integrating EEG measurement with non-invasive brain stimulation therapies and offering cloud-based analysis.

Emerging players

  • Neurable: US-based neurotechnology company building EEG-enabled wearable devices and brain-computer interface software for productivity, wellness, and clinical applications. Comparable as an emerging EEG wearable and analytics peer, with overlap in consumer/wellness brain health use cases adjacent to iMediSync's iSyncMe.
  • Dreem: France-based neurotechnology company with a consumer EEG headband for sleep and cognitive monitoring, plus a clinical research arm developing EEG biomarkers. Comparable to iMediSync on dry EEG + cloud biomarker platform strategy, though primarily consumer/sleep-oriented rather than dementia.

Broad incumbents

  • Natus Medical: US-listed incumbent in neurodiagnostic, EEG, and newborn screening equipment. Comparable as a broad EEG/neurology hardware incumbent selling to hospitals worldwide, though its portfolio spans many adjacent device categories beyond iMediSync's brain health focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

iMediSync social profiles

Digital presence

iMediSync compliance and trust

Trust signal

Compliance4 records

iMediSync financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iMediSync leadership team

Management profile

Number of profiles

Profiles2 records

iMediSync subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

iMediSync funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iMediSync M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iMediSync

What does iMediSync do?

iMediSync develops and sells wireless dry-electrode EEG headsets (iSyncWave and iSyncMe) integrated with near-infrared photobiomodulation (PBM) therapy, connected to a cloud-based AI analytics platform (iSyncBrain for QEEG analysis, iSyncHeart for HRV analysis). The platform performs automated brain health screening, age- and sex-normed comparison, and AI-based disease biomarker detection for conditions such as Alzheimer's, amnestic mild cognitive impairment, Parkinson's, depression, and stroke cognitive impairment. The offering is sold as regulated medical device hardware plus SaaS analytics subscriptions to hospitals, clinics, government health programs, and wellness/senior care operators.

Is iMediSync a public or private company?

iMediSync is a private company. It is classified as venture growth investor backed and is currently operating.

When was iMediSync founded?

iMediSync was founded in 2012. It employs 11 to 50 people.

Where is iMediSync based?

iMediSync is headquartered in Seoul, South Korea, in the Asia region.

How does iMediSync make money?

Four revenue lines are on record. Hardware Device Sales (iSyncWave, iSyncMe) is the primary driver. The others are cloud-Based AI Analytics Platform (iSyncBrain, iSyncHeart), software Medical Device Licensing and professional Services and Training.

Who are iMediSync's main competitors?

Direct peers on record are BrainScope, Emotiv, Ceribell, Cumulus Neuroscience, Wave Neuroscience, Compumedics and Neuroelectrics. Emerging players are Neurable and Dreem. Natus Medical is listed as a broad incumbent.

Does iMediSync have an API?

No public API is recorded for iMediSync.

What industry is iMediSync in?

iMediSync's product category is Digital Mental Health Diagnostics. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACAPAD, Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireFirst-ever integrated EEG and neurotherapeutics device iSyncWave wins the 2022 Red Dot Design AwardiMediSync announced that its iSyncWave, a dry EEG headset for digital mental healthcare, has won the 2022 Red Dot Design Award. The device utilizes AI-based analysis of brainwave data to support clinical applications in neurology and psychology across South Korea and international partners. The company is currently pursuing U.S. FDA approval to facilitate global market expansion.ThebelliMedicine surpasses a corporate value of '100 billion' after 9 years of establishment.Bio startup iMedisyn completed a Series C fundraising round of 7.6 billion won, achieving a post-money valuation of 140 billion won. The investment was led by A Ventures, K-Ron Ventures, and Withwin Investment, marking the company's first funding in over two years since its Series B round. This valuation milestone reflects the strong market confidence in iMedisyn's AI-driven diagnostic tool, iSyncBrain, which detects early signs of dementia using brain wave analysis.PR NewswireiMediSync Successfully Launches the Future of Tele-Medicare at CES 2022iMediSync, a biotech startup from Seoul, South Korea, successfully debuted at CES 2022 to showcase its iSyncWave dry EEG helmet featuring EEG and HRV measurement with age/gender matching analysis. The product attracted over 300 daily visitors including doctors, clinicians, and potential business partners, generating significant interest in collaboration and global market expansion. The company expects an IPO this year and is pursuing FDA and CE regulatory approvals to expand further into the digital healthcare and neurology markets.PR NewswireiMediSync lança com sucesso o futuro da Telemedicina na CES 2022iMediSync, a Seoul-based biotech startup, successfully debuted at CES 2022 showcasing its iSyncWave wireless EEG headset with dry electrode technology, which provides EEG and HRV analysis with age/gender matching using what the company claims is the world's first database of over 1,800 healthy brain wave norms. The product attracted over 300 daily visitors including doctors, clinicians, and influencers, and the company is pursuing regulatory approvals from the FDA and CE while planning an IPO in 2022.PR NewswireiMediSync lanza con éxito "The Future of Tele-Medicare" (el futuro de la telemedicina) en el CES 2022iMediSync, a Seoul-based biotech startup, successfully debuted its iSyncWave wireless EEG/HRV brain scanning device at CES 2022, attracting over 300 visitors daily including doctors, clinicians, and investors. The company has Korean FDA approval for its product and software, and is pursuing FDA and CE regulatory approvals in the first half of 2022 to expand into global markets. iMediSync, which expects to go public this year, is in discussions with pharmaceutical companies and research organizations for partnerships and collaboration in digital healthcare.Mail OnlineCES kicks of with its 'Unveiled' event that showcased Airxom Mask, Morari Medical and iMediSync | Daily Mail OnlineThe Consumer Technology Association (CTA) kicked off CES 2022 with its 'Unveiled' event in Las Vegas, showcasing innovations from companies such as Airxom Mask, Morari Medical, and iMediSync. Key products included an active-filter face mask for COVID-19 protection, a wearable patch for premature ejaculation, and a portable AI-driven brain scanner for mental health diagnostics. The event also highlighted award winners like Kura Technologies for AR glasses and GAF Energy for solar shingles, while major tech firms notably skipped in-person attendance due to the pandemic.PR NewswireiMediSync Unveils World's First Integrated Brain Scanning, Photo-Enhancing and Remote Care Solution at CES 2022iMediSync is launching its iSyncWave comprehensive early mental health diagnostics and remote care solution at CES 2022 in Las Vegas, following 10 years of research and clinical trials. The platform uses EEG and HRV analysis to detect early signs of mental conditions such as Alzheimer's dementia within 10 minutes, with clinical trials confirming over 90% accuracy. The company, headquartered in Seoul, Korea, aims to develop early-detecting biomarkers for neurological disorders including Parkinson's, ADHD, and depression.PR NewswireiMEDISYNC UNVEILS WORLD'S FIRST INTEGRATED WIRELESS BRAIN EEG at CES 2022iMediSync announced the unveiling of its iSyncWave, a wireless brain EEG device integrating hardware, software, and telehealth capabilities, at CES 2022 in Las Vegas. The device utilizes AI algorithms to provide mental health screening and predictive analysis results in just 10 minutes. This launch follows recent FCC approval for export to the EU, Asia, and Australia, with ongoing cooperation with global pharmaceutical companies.Business TodayCES 2021: iMediSync to showcase iSyncWave headset, aims at early Alzheimer's dementia detectionSouth Korean biomedic start-up iMediSync will showcase its iSyncWave EEG brain mapping and LED-therapeutic device at CES 2021, designed for early detection of Alzheimer's dementia and other neuropsychiatric disorders. The device uses AI brain mapping technology and demonstrated over 90% accuracy in multicenter clinical trials for detecting pre-clinical Alzheimer's dementia. The company is also conducting research for biomarkers for other neurological conditions including coma, ADHD, depression, and Parkinson's Disease.